Advagene Biopharma Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported net loss was TWD 55.98 million compared to TWD 39.84 million a year ago. Basic loss per share from continuing operations was TWD 1.13 compared to TWD 0.83 a year ago.